Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health, Inc. (NASDAQ:JAGX) has announced an investor call on December 17, 2020, to discuss recent developments following the adjournment of its Special Meeting of Stockholders.

This meeting, initially held on December 9, was postponed to December 22, allowing time to gather additional proxies. The company is working to comply with Nasdaq's bid price requirement and has secured a stay from the Listing Council.

Jaguar's efforts include expanding patient access for Mytesi, initiating a Phase 3 clinical trial for cancer therapy-related diarrhea, and considering a merger with a European SPAC.

Jaguar Health, Inc. (JAGX) has received notice from the Nasdaq Listing Council regarding its compliance with the $1.00 minimum bid price requirement. The Council will review the decision made by the Nasdaq Listing Qualifications Panel, which granted Jaguar until December 23, 2020, to remedy the bid price deficiency. The Listing Council has stayed the Panel's decision during its review. CEO Lisa Conte expressed optimism, citing efforts to improve financial prospects through expanded patient access programs and a recent $6 million capital infusion.

Jaguar Health, Inc. (NASDAQ:JAGX) announced a fifth amendment to its accounts receivable agreement with Oasis Capital, LLC, allowing the purchase of additional accounts receivable totaling $3,810,587.04 from October 13 to December 2, 2020. This financing represents a strategic move to secure non-dilutive capital as the company sees growing sales of its Mytesi drug product.

Oasis will pay $1,619,499.49 for these receivables and charge a 5.45% fee. This indicates an increase in the financing percentage compared to previous agreements.

Jaguar Health (NASDAQ:JAGX) and Napo Pharmaceuticals plan to develop crofelemer for treating inflammatory diarrhea in long-hauler COVID-19 patients in Europe. Preliminary discussions with Swiss Growth Forum involve a SPAC merger, offering Napo a cash license fee between $2M-$10M and at least $20M for European operations. Crofelemer, an FDA-approved medication for noninfectious diarrhea in HIV/AIDS patients, aims to address chronic gastrointestinal issues post-COVID. Jaguar emphasizes the significance of early diagnosis to improve long-term recovery outcomes.

Jaguar Health, Inc. (NASDAQ:JAGX) has released a podcast interview with CEO Lisa Conte via The Wall Street Resource. The company focuses on developing plant-based, non-opioid medications for gastrointestinal issues, particularly targeting chronic diarrhea. Their flagship product, Mytesi (crofelemer), is FDA-approved for treating non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company emphasizes sustainable sourcing of ingredients, highlighting ecological integrity in harvesting practices.

Jaguar Health reported third quarter 2020 financial results, showing significant growth in Mytesi product revenue totaling approximately $2.8 million, a 280% increase from $1.0 million in the same quarter of 2019. Gross sales reached approximately $6.3 million, up 332% year-over-year. Despite increased sales, the company recorded a net loss of $7.9 million, compared to $7.6 million in Q3 2019. Operating expenses rose to $8.1 million, influenced by higher general and administrative costs, including a $2.5 million trial delay fee.

Jaguar Health, Inc. (NASDAQ:JAGX) is set to file its Q3 2020 10-Q report on November 16, 2020. Management will host a conference call at 8:30 a.m. ET to discuss the financial results and provide business updates. Investors can join via dial-in numbers, with a replay option also available. The company is focused on developing plant-based pharmaceuticals to address GI distress, particularly chronic diarrhea. Notably, its product Mytesi^® is FDA-approved for treating diarrhea in adults with HIV/AIDS.

Jaguar Health, Inc. (NASDAQ:JAGX) announced that it received an extension from the Nasdaq Hearings Panel until December 23, 2020, to comply with the minimum bid price requirement for continued listing. The company must maintain a bid price of at least $1.00 per share for ten consecutive business days. Jaguar's recent efforts include expanded access programs for Mytesi and a $6 million royalty-based capital infusion. Additionally, Napo Pharmaceuticals initiated a pivotal Phase 3 trial for Mytesi in adult cancer patients experiencing diarrhea.

Jaguar Health (NASDAQ:JAGX) is hosting its inaugural "Diarrhea Dialogues" virtual event on October 20, 2020, from 3:00 PM to 4:30 PM ET, focused on supportive care for cancer patients experiencing diarrhea from cancer therapies. Key experts, including Jaguar's leadership and oncologists, will discuss the impact of diarrhea on cancer treatment and the importance of patient-physician dialogue. Jaguar's subsidiary, Napo Pharmaceuticals, has initiated a pivotal Phase 3 trial for crofelemer (Mytesi) in preventing cancer therapy-related diarrhea, currently approved for HIV/AIDS-related diarrhea relief.